Piyasa bakış

The Global Auto-Injectors Market is projected to experience substantial growth, increasing from USD 9,344 million in 2023 to USD 19,668 million by 2028, with a Compound Annual Growth Rate (CAGR) ile ilgili 16.05% tahmin dönemi boyunca (2023-2028).

Auto-Injectors, referring to syringes containing spring-loaded needles with preloaded medication, are activated when pressed against the body, delivering a calculated dose of medication.

Several factors drive market growth, including increasing demand for patient convenience, a rise in chronic and lifestyle diseases, and technological advancements. The World Health Organization reports that over 16 billion injections were administered worldwide annually in 2021, contributing to the demand for auto-injectors.

Chronic diseases are expected to increase by 57% by 2020, with 60% of this burden in emerging markets, making them leading causes of disability and morbidity worldwide. The prevalence of conditions like cancer, diabetes, and tuberculosis has driven the demand for auto-injectors.

The use of auto-injectors has provided numerous benefits to both patients and healthcare professionals, such as simplified self-administration, reduced anxiety, improved safety, and better compliance. Market players are seizing the significant opportunities in the sector, employing strategies like collaborations, acquisitions, new product launches, and expansions to expand their presence. For instance, Owen Mumford Pharmaceutical Services introduced its Aidaptus auto-injector platform in September 2021, and Otsuka Pharmaceutical Co., Ltd.. applied for an additional dosage form, the auto-injector, for AJOVY Subcutaneous Injection 225 mg in July 2021.

While these factors are expected to drive market growth over the forecast period, challenges such as the preference for alternative dosage delivery modes and regulatory hurdles may impede the market’s expansion.

Pazar Segmentasyonu

Pazar çeşitli faktörlere göre bölümlere ayrılmıştır, including application, type, end user, ve coğrafya.

Uygulamaya Göre Segmentasyon
Rheumatoid Arthritis
Multiple Sclerosis
Anaphylaxis
Other Applications (Cardiovascular Diseases, Diabetes, Migraines, Psoriasis, and Anemia)

Segmentation by Type
Disposable Autoinjectors
Reusable Autoinjectors

Segmentation by End User
Home Care Settings
Hospital & Clinics
Other End Users

Coğrafyaya Göre Segmentasyon
Kuzey Amerika – Amerika Birleşik Devletleri, Kanada, Meksika
Avrupa – Birleşik Krallık, Almanya, Fransa, İtalya, ispanya, and Rest of Europe
Asia-Pacific – Çin, Japonya, Hindistan, Avustralya, Güney Kore, and Rest of Asia-Pacific
Latin Amerika – Brezilya, Arjantin, and Rest of Latin America
Middle East and Africa – GCC, Güney Afrika, and Rest of Middle East and Africa

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the immune system attacking the joints, leading to inflammation of the synovium and causing pain and swelling in and around the joints. This condition predominantly affects the elderly population, with females experiencing a higher prevalence compared to males. According to the United Nations World Population Prospects 2020 report, the number of individuals aged 65 years or above is projected to more than double by 2050, reaching 727 million worldwide. As arthritis is more common in the geriatric population, this demographic shift is expected to drive growth in the segment over the forecast period.

Several recent studies have shown that a majority of rheumatoid arthritis patients who use an autoinjector for treatment find the device comfortable to use and experience better outcomes than those who rely on someone else to administer injections. bunlara ek olarak, initiatives by market players are contributing to the market’s expansion. For instance, in March 2022, NORDIC PHARMA, a SEVER Life Sciences company, submitted a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet, intended for treating severe disabling active rheumatoid arthritis (RA) and controlling severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy. The approval of such drugs is expected to drive market growth.

Thus, considering the aforementioned factors, the market segment is expected to exhibit growth over the forecast period.

North America is anticipated to hold a significant share in the global disposable auto-injectors market during the forecast period. This is attributed to factors such as early adoption of technologically advanced products, product approvals, and the rising prevalence of chronic diseases in the region. The high incidence of chronic diseases, including cancers, also contributes to market growth in North America. According to Globocon 2020, the United States recorded 2,281,658 new cancer cases and 612,390 deaths in 2020. Breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809) cancers.

Furthermore, technological advancements, the influx of new players, and swift adoption of advanced products are aiding market growth in the United States. For instance, in April 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd., announced the availability of the autoinjector device for AJOVY (fremanezumab-vfrm) injection in the United States. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

Rekabetçi Ortam

The Auto-Injectors market is characterized by intense competition and comprises numerous major players. Prominent companies such as Abbvie, Amgen, AstraZeneca, Bayer, Becton, Dickinson and Company, Biogen, Eli Lilly, Novartis, Teva Pharmaceuticals, and Ypsomed, among others, command a significant market share in the Auto-Injectors market.

Recent Industry Developments

In May 2022, Jabil Healthcare, a division of Jabil Inc., introduced the Qfinity autoinjector platform. This platform offers a straightforward, reusable, and modular solution for subcutaneous (SC) drug self-administration, all at a more cost-effective price compared to other alternatives available in the market.

In the same month of May 2022, Stevanato Group S.p.A. entered into an exclusive agreement with Owen Mumford Ltd., a prominent medical device developer and manufacturer, for its Aidaptus auto-injector.

Cevaplanan Anahtar Sorular

What is the study period of the Global Auto-Injectors Market?
The Global Auto-Injectors Market is studied from 2018 ile 2028.

What is the growth rate of the Global Auto-Injectors Market?
The Global Auto-Injectors Market is experiencing a growth rate of 16.05% over the next 5 yıllar.

What is the size of the Global Auto-Injectors Market?
The Global Auto-Injectors Market is expected to reach USD 9,344 million in 2023 and is projected to grow at a CAGR of 16.05% to reach USD 19,668 million by 2028.

Which region has the highest growth rate in the Global Auto-Injectors Market?
Asia Pacific is witnessing the highest CAGR growth over the period from 2018 ile 2028.

Which region has the largest share in the Global Auto-Injectors Market?
North America holds the highest market share as of 2021.

Who are the key players in the Global Auto-Injectors Market?
The major companies operating in the Global Auto-Injectors Market are Ypsomed, Abbvie, Amgen, Teva Pharmaceuticals, and Biogen.